NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI - News) today announced that it has initiated a Phase 2, double-blinded, placebo- and active-controlled, dose-finding clinical trial to evaluate the safety and efficacy of its novel compound, becocalcidiol, for the treatment of psoriasis.
